Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of
This study will evaluate the immunogenicity, safety, and tolerability of rF1V-1018 vaccine
| Condition(s) | Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Summary | This study will evaluate the immunogenicity, safety, and tolerability of rF1V-1018 vaccine |
| Who can participate | Inclusion Criteria: 1. Adults 18 to 55 years of age 2. Healthy participants or participants with stable pre-existing medical conditions Pre-existing stable medical condition means a participant who: has full capacity of daily activity and no major medication modification within 3 months prior to Day 1; has not undergone surgical or minimally-invasive intervention or had any hospitalization/emergency room visit for the specific medical condition. 3. Able to comply with the protocol schedule and procedures 4. Able and willing to provide written informed consent 5. If female of child-bearing potential and heterosexually active, has practiced adequate contraception for at least 28 days prior to vaccination, has negative pregnancy tests just prior to vaccination, and has agreed to continue adeq |
| Ages | 18 Years to 55 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | Dynavax Technologies Corporation |
| Locations | Miami, Florida, United States; El Dorado, Kansas, United States; Las Vegas, Nevada, United States |
| Start date | 2025-09-11 |
| NCT ID | NCT07207408 |
| Official listing | https://clinicaltrials.gov/study/NCT07207408 |